ILiAD Biotechnologies

New York, United States

ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.

Feb 2026

Series D

Biotechnology Clinical Trials Health Care Pharmaceutical

Top Investors

RA Capital ManagementJanus Henderson InvestorsBNP Paribas Asset ManagementNational Institute of Allergy and Infectious DiseasesKnott Partners

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about ILiAD Biotechnologies

Who are ILiAD Biotechnologies's investors?

ILiAD Biotechnologies's investors include RA Capital Management, Janus Henderson Investors, BNP Paribas Asset Management, National Institute of Allergy and Infectious Diseases, Knott Partners.

Where is ILiAD Biotechnologies headquartered?

ILiAD Biotechnologies is headquartered in New York, United States.

What does ILiAD Biotechnologies do?

ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.

What stage is ILiAD Biotechnologies at?

ILiAD Biotechnologies is at the Series D stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 10, 2026.

MLA

"ILiAD Biotechnologies — Funding & Investors." VCBacked, February 10, 2026, https://www.vcbacked.co/company/iliad-biotechnologies. Accessed July 1, 2026.

APA

VCBacked. (2026). ILiAD Biotechnologies — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/iliad-biotechnologies

Wikipedia (cite web)

{{cite web |title=ILiAD Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/iliad-biotechnologies |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 10, 2026.